4.75  -0.38 (-7.41%)		07-10 16:00
Open: 5.03 High: 5.1 Volume: 2,192,542		Pre. Close: 5.13 Low: 4.75 Market Cap: 457(M)

Short term
Mid term
Targets	6-month :	6.33	1-year :	7.39
Resists	First :	5.42	Second :	6.33
Pivot price	5
Supports	First :	4.36	Second :	3.7
MAs	MA(5) :	4.94	MA(20) :	4.83
	MA(100) :	3.59	MA(250) :	5.34
MACD	MACD :	0.2	Signal :	0.3
%K %D	K(14,3) :	44.3	D(3) :	57.2
RSI	RSI(14): 53.7
52-week	High :	11.45	Low :	1.07

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ RZLT ] has closed below the lower bollinger band by 7.1%. Bollinger Bands are 58.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	5.11 - 5.13	5.13 - 5.15
Low:	4.69 - 4.72	4.72 - 4.74
Close:	4.71 - 4.75	4.75 - 4.79

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Tue, 07 Jul 2026
Rezolute (RZLT) CEO logs automatic RSU tax-withholding share sale in Form 4 - Stock Titan

Tue, 07 Jul 2026
Rezolute (RZLT) CFO logs RSU tax sell-to-cover, retains 411,400 shares - Stock Titan

Sat, 04 Jul 2026
RZLT - Rezolute Inc Options - Finviz

Thu, 02 Jul 2026
RZLT News | REZOLUTE INC (NASDAQ:RZLT) - ChartMill

Thu, 25 Jun 2026
RZLT Forecast — Price Target — Prediction for 2027 - TradingView

Wed, 10 Jun 2026
Positive Signs As Multiple Insiders Buy Rezolute Stock - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	96 (M)
Shares Float	66 (M)
Held by Insiders	10.1 (%)
Held by Institutions	90.3 (%)
Shares Short	13,810 (K)
Shares Short P.Month	14,580 (K)

EPS	-0.82
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.23
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-48.8 %
Return on Equity (ttm)	-81.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.9
Qtrly Earnings Growth	0 %
Operating Cash Flow	-73 (M)
Levered Free Cash Flow	-44 (M)

PE Ratio	-5.87
PEG Ratio	0
Price to Book value	3.86
Price to Sales	0
Price to Cash Flow	-6.23

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.